– Clinically Meaningful Benefit Observed at Both ATH434 Doses Studied – – Achieved Statistical Significance with Up to 48% Slowing of Clinical Progression on UMSARS Rating Scale – – Key MRI Biomarker Shows Iron Stabilization in MSA Affected Brain Regions – – ATH434 Demonstrated a Favorable Safety Profile – – Webcast Held Yesterday with Access to the Recording Below – MELBOURNE, Australia and SAN FRANCISCO, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterit

Altria Group stock dipped in premarket trading Thursday after the maker of Marlboro cigarettes reported fourth-quarter and full-year earnings that matched analysts’ estimates. Shares of Altria Group dipped 0.3% to $52.51.

Tesla's earnings disappoint, sparking mixed reactions from analysts as the company shifts focus beyond EVs

Fed Chair Powell highlights AI and tech's role in rising asset prices, while interest rates add pressure to financial conditions

Kazia Therapeutics Limited (NASDAQ: KZIA) an oncology-focused drug development company, is pleased to announce the regulatory approval and launch of a clinical trial evaluating the combination of paxalisib and immunotherapy in patients with advanced breast cancer. This novel treatment combination offers what is believed to be a unique approach to targeting this highly aggressive and treatment-resistant type of breast cancer.

The Jerusalem-based company said it had a loss of 9 cents per share. Earnings, adjusted for one-time gains and costs, came to 13 cents per share. The results surpassed Wall Street expectations.

The average estimate of six analysts surveyed by Zacks Investment Research was for earnings of 64 cents per share. The satellite radio company posted revenue of $2.19 billion in the period, also beating Street forecasts. Five analysts surveyed by Zacks expected $2.17 billion.

Elon Musk's ambitious plans for Tesla include launching an unsupervised self-driving robotaxi in Austin, Texas, and ramping up production of cheaper electric vehicles.

We recently published a list of the 12 Best Stocks to Buy in 2025 for Beginners. In this article, we are going to take a look at where Thermo Fisher Scientific Inc. (NYSE:TMO) stands against other best beginner stocks to buy in 2025. Stock Market Outlook for 2025 On December 12, Tom Lee, Fundstrat Global […]

The financing package includes a construction/bridge loan facility and a letter of credit facility.